NSW Health logs 1,180 emergency presentations tied to unapproved peptide use
Monthly cases rose from five in July 2025 to more than 217 in September 2026, with BPC-157, TB-500, GHK-Cu, CJC-1295 and retatrutide named.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 22 17:50 ETSource: Nambucca Valley News Of The Area
The wire
- 01NSW Health surveillance recorded 1,180 emergency department presentations associated with peptide use between 1 July 2025 and 30 September 2026, up from five monthly presentations at the start of that window.
- 02Chief Health Officer Dr. Kerry Chant said none of the named peptides is approved in Australia for any purpose and warned that labels, purity claims and influencer endorsement are not proof of contents.
- 03NSW Health works with the Therapeutic Goods Administration and law enforcement to trace product sources; the surveillance data does not establish which products or contaminants caused individual presentations.
From the source
Read at nambuccavalley.newsofthearea.com.auSurge in hospital presentations linked to peptide use prompts warning from NSW Health
PEPTIDE use has led to a sharp increase in emergency department presentations in the State, according to NSW Health.
